Galinpepimut-S
Phase 3Biologic
Galinpepimut-S is one of 27 biologic programs targeting AIN. It is currently in Phase 3.
1
Indications
7
Total Trials
1
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
32 competitors in AIN
#DrugCompanyPhaseTrials
1Lynparza
AstraZenecaPhase 2
Avastin
RochePhase 2
Plaquenil
Jazz PharmaceuticalsPhase 2
Reblozyl
Bristol-Myers SquibbPhase 2
Jevtana
SanofiPhase 2
GM-CSF
YY-mAbs Therapeutics
Phase 3
Paraplatin
AAvyxa
Phase 2
Ayvakit
BBlueprint Medicines
Phase 2
Brukinsa
BBeOne Medicines
Phase 2
Vepesid
AAvyxa
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma1 trial
Advanced Cancers1 trial
Mesothelioma1 trial
Malignant Pleural Mesothelioma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Galinpepimut-S. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- SSellas Life Sciences Group